Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do you have a link for video? Thank you in advance
Thanks for the video!
$COEP
$COEP Sequire Spotlight Presents Coeptis Therapeutics Inc. (COEP): Developing Innovative Cell Therapy
Yes, looking much better. $COEP trading nearly 2x its 10-day average volume as we have entered Power Hour...UP almost 5%, with some nice volume after lunch.
Looking much better! Lots of buying came in.
Exciting and Thin here. Low float can take us higher quickly. $COEP
Moving back up..nice!!
Thank you for sharing that link to the $COEP video
Accumulating here, way undervalued at these levels!
$COEP
$COEP Big Things coming as Coeptis Therapeutics CEO David Mehalick telling Proactive SNAP-CAR, which Coeptis licensed from the University of Pittsburgh, is being researched with tech that can be adapted to different cancer indications #nasdaq #coep #cancer #stock
COEP...................https://stockcharts.com/h-sc/ui?s=COEP&p=W&b=5&g=0&id=p86431144783
$COEP trading just over 70% of its 10-day average volume with Power Hour getting closer... trading in a tighter range today.
Will be interesting to see what ShareIntel finds out about $COEP...
David Wenger, President and Chief Executive Officer of ShareIntel, stated, "We look forward to helping Coeptis identify potential abusive and illegal naked short selling. A company's most valuable currency is its stock and it is important to protect shareholders from egregious trading activities."
$COEP Coeptis Therapeutics Inc (COEP) More Companies Fight Back Against Market Manipulation and Illegal Short Selling; Here are Four Stocks in the News : Companies like Genius Group Limited (NYSE:GNS), Helbiz, Inc. (NASDAQ:HLBZ), CannaPharmaRx, Inc. (OTC:CPMD) and Verb Technology Company, Inc. (NASDAQ:VERB) have started the proactive process of establishing task forces and investigative activity.
https://quantisnow.com/insight/4020952
$COEP 1.48 ready to go, heading for a breakout!
$COEP CEO: "We want to ensure that Coeptis is not the target of market manipulation," said Dave Mehalick, President and CEO of Coeptis. "ShareIntel's proprietary analytics will identify reporting anomalies among market makers, banks, broker-dealers and clearing firms as it tracks share ownership and identifies suspicious trading activity."
Sell the News, it's the OTC norm...
$COEP trading 3x over its 10-day average volume as Power Hour looms closer... holding steady near yesterday's close.
Very nice news always accompanied with the price going down…
Very nice $COEP News... Protecting shareholder value.
"We want to ensure that Coeptis is not the target of market manipulation," said Dave Mehalick, President and CEO of Coeptis. "ShareIntel's proprietary analytics will identify reporting anomalies among market makers, banks, broker-dealers and clearing firms as it tracks share ownership and identifies suspicious trading activity."
Thin to $1.30’s apparently
"We want to ensure that Coeptis is not the target of market manipulation," said Dave Mehalick, President and CEO of Coeptis. "ShareIntel's proprietary analytics will identify reporting anomalies among market makers, banks, broker-dealers and clearing firms as it tracks share ownership and identifies suspicious trading activity."
$COEP
NEWS - Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling
Coeptis strengthens measures to protect shareholder interests through ShareIntel's investigation and due diligence services
WEXFORD, Pa., Feb. 7, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced the Company has retained Shareholder Intelligence Services, LLC ("ShareIntel") for a 12-month, full-service agreement to review the trading patterns of the Company's common stock; monitor, identify and reconcile discrepancies; and target illegal short selling activities.
ShareIntel gathers and analyzes shareholder trading data through its DRIL-DownTM process, a technology platform that examines equity flows and reveals suspicious, aberrant, and/or unusual trading activity. The tool aims to help management to identify, interpret and communicate shareholder and broker-dealer movement to the market.
"We want to ensure that Coeptis is not the target of market manipulation," said Dave Mehalick, President and CEO of Coeptis. "ShareIntel's proprietary analytics will identify reporting anomalies among market makers, banks, broker-dealers and clearing firms as it tracks share ownership and identifies suspicious trading activity."
David Wenger, President and Chief Executive Officer of ShareIntel, stated, "We look forward to helping Coeptis identify potential abusive and illegal naked short selling. A company's most valuable currency is its stock and it is important to protect shareholders from egregious trading activities."
Shareholder Intelligence Services, LLC – (ShareIntel)
ShareIntel is an application service provider retained by public companies to obtain, aggregate, track and analyze shareholder trading information. This process is managed through a proprietary patent pending web-based application known as the "Data Repository Information Link" system DRIL-DownTM.
In addition to its core business, ShareIntel can provide value-added custom consulting services to help client companies maximize the utility of our analyses. ShareIntel is a part of the $5 billion plus rapidly growing Software-as-a-Service ("SaaS") industry.
The ShareIntel solution empowers the public company CEO's with unique analytical tools to manage their investment bankers, legal counsel, investor relations, shareholders and more. ShareIntel creates meaningful hard and soft dollar savings by providing "instant" and actionable analytic metrics to coordinate and monitor corporate governance, regulatory compliance, corporate finance, due diligence, public offering market surveillance, mergers, acquisitions, investor relations, shareholder communications, blue sky compliance, road show planning and more.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Global Market following the business combination; (2) the risk that the business combination disrupts current plans and operations of Company as a result of the consummation of the business combination; (3) the inability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (4) the risks that the Company's products in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (5) costs related to the business combination; (6) changes in applicable laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (8) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
CONTACTS
Coeptis Therapeutics, Inc.
Andy Galy
Sr. VP of Communications
504-416-6965
andy.galy@coeptistx.com
Investors
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
jnugent@tiberend.com
Media
Bill Borden
732-910-1620
bborden@tiberend.com
https://finance.yahoo.com/news/coeptis-therapeutics-shareintel-enter-shareholder-130000396.html
Watch @coeptistx CEO Dave Mehalick's presentation at the Sequire Biotech Conference: https://biotech.sequireevents.com/recording?session_id=6216e06a-089e-40cd-94be-6486b13ae887 $COEP
#CellTherapy #CARTcell #Immunotherapy
@SRAXmedia
$COEP In recent news, Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program https://finance.yahoo.com/news/coeptis-therapeutics-enters-sponsored-research-123000182.html
$COEP trading just under 70% of its 10-day average volume as we start Power Hour...with the BID higher than the lows of the day.
$COEP already hit $1.55 this morning...thins out after $1.49, let's see if Power Hour pushes us past that.
$COEP Profile: Shareholder concentration and Top Institutional Holders https://www.cnbc.com/quotes/COEP?tab=profile
$COEP trading 1.3x over its 10-day average volume as Power Hour looms closer... slightly green. Let's see if volume continues to pick up.
This is old. It’s already happened
$COEP WEXFORD, Pa., Jan. 31, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced a sponsored research agreement with the University of Pittsburgh to advance pre-clinical development of SNAP-CAR T cells targeting HER2 as well as identify opportunities to expand the applicability of SNAP-CAR in oncology. SNAP-CAR, which Coeptis licensed from the University of Pittsburgh, is a multi-antigen chimeric antigen receptor T cell (CAR T) technology that can be adapted to different cancer indications, including hematologic and solid tumors.
$COEP will be uplisting via a SPAC BHSE at a ratio of 2.9 COEP is now 3, which equals 8.7 for BHSE, there is also BHSEW warrants that look cheap 8k https://www.otcmarkets.com/filing/html?id=16157944&guid=jEz-kemBceBUdth
Let’s not spread that news. Apparently no one cares a couple days ago as this goes down.
Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program https://finance.yahoo.com/news/coeptis-therapeutics-enters-sponsored-research-123000182.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
Looking for another bullish run $COEP
From their news: "We are very excited to continue our work with the University of Pittsburgh to advance the development of SNAP-CAR towards a potential first indication: HER2-expressing ovarian cancer," said Dave Mehalick, President and CEO of Coeptis Therapeutics Holdings. "If successful, this could represent a potential breakthrough in the treatment of HER2-positive cancers and the applicability of CAR T to treat a range of solid tumors, including ovarian and breast cancer, as well as hematologic cancers. We look forward to working with Dr. Lohmueller, Dr. Deiters, and the research team at the University of Pittsburgh, as well as IQVIA, to prioritize the initial target indication for advancing SNAP-CAR through the IND process and into the clinic."
$COEP
Undervalued at these levels!
$COEP
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/. $COEP
Dave Mehalick, President and CEO of Coeptis Therapeutics Holdings stated,
$COEP Coeptis to collaborate with the University of Pittsburgh to expand pre-clinical development of SNAP-CAR T cells targeting HER2-positive cancers
WEXFORD, Pa., Jan. 31, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced a sponsored research agreement with the University of Pittsburgh to advance pre-clinical development of SNAP-CAR T cells targeting HER2 as well as identify opportunities to expand the applicability of SNAP-CAR in oncology. SNAP-CAR, which Coeptis licensed from the University of Pittsburgh, is a multi-antigen chimeric antigen receptor T cell (CAR T) technology that can be adapted to different cancer indications, including hematologic and solid tumors.
Under the terms of the sponsor research agreement, the University of Pittsburgh will conduct pre-clinical research on the SNAP-CAR technology necessary to enable the filing of an Investigational New Drug (IND) application for clinical trials involving SNAP-CAR T cells targeting HER2-positive cancers. Specifically, researchers at the University of Pittsburgh, led by principal investigator, Jason Lohmueller, Ph.D., Assistant Professor of Surgery and Immunology in the Division of Surgical Oncology Research, and Alexander Deiters, Ph.D., Professor of Chemistry, will work in coordination with Coeptis' CRO partner, IQVIA, to develop a treatment strategy for ovarian cancer (or other solid tumors) in animals and identify a lead candidate for first-in-human clinical development. HER2 is a tumor-associated antigen (TAA) that is overexpressed in approximately 28%1 of ovarian cancer tissues and 25% of patients with breast cancer2.
"We are very excited to continue our work with the University of Pittsburgh to advance the development of SNAP-CAR towards a potential first indication: HER2-expressing ovarian cancer," said Dave Mehalick, President and CEO of Coeptis Therapeutics Holdings. "If successful, this could represent a potential breakthrough in the treatment of HER2-positive cancers and the applicability of CAR T to treat a range of solid tumors, including ovarian and breast cancer, as well as hematologic cancers. We look forward to working with Dr. Lohmueller, Dr. Deiters, and the research team at the University of Pittsburgh, as well as IQVIA, to prioritize the initial target indication for advancing SNAP-CAR through the IND process and into the clinic."
"Current CAR T therapies are designed to target specific tumor antigens that correspond to a specific cancer indication. This approach has proven effective in certain cancer types but limits the applicability of those CAR T therapies," said Dr. Lohmueller. "SNAP-CAR has been designed as a 'universal' CAR T cell therapy platform that can be adapted to different tumor antigens and cancer indications. We are eager to work with the teams at Coeptis and IQVIA to begin the pre-clinical development of a potential lead candidate targeting HER2-positive ovarian cancer, as well as optimizing the platform to increase its value potential."
About SNAP-CAR
SNAP-CAR, which Coeptis Therapeutics licensed from the University of Pittsburgh, is designed to be a "universal" CAR T cell therapy platform that can be adapted to different cancer indications. Instead of directly binding to a target on the tumor cell, CAR T cells are co-administered with one or more antibody adaptors that bind to the tumor cells and are fitted with a chemical group that irreversibly connects them to the SNAP-CAR on the therapeutic cells via a covalent bond. Pre-clinical studies in mice have demonstrated that by targeting tumors via antibody adaptor molecules, the SNAP-CAR therapy provides a highly programmable therapeutic platform.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/.
About the University of Pittsburgh
A nonsectarian, coeducational, state-related, public research university founded in 1787, the University of Pittsburgh (Pitt) is a member of the prestigious by-invitation-only Association of American Universities and internationally renowned as a leading center of learning and research in the arts, sciences, humanities, professions and health sciences. Comprising a Pittsburgh campus, which is home to 16 undergraduate, graduate and professional schools, and four Western Pennsylvania regional campuses, Pitt offers nearly 500 distinct degree programs and confers more than 8,500 degrees annually. Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1998 and is ranked among the top 10 American research universities nationally in terms of total federal science and engineering research and development obligations. For more information, visit www.pitt.edu.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Global Market following the business combination; (2) the risk that the business combination disrupts current plans and operations of Company as a result of the consummation of the business combination; (3) the inability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (4) the risks that the Company's products in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (5) costs related to the business combination; (6) changes in applicable laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (8) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
CONTACTS
Coeptis Therapeutics, Inc.
Investors
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
jnugent@tiberend.com
Media
David Schemelia
609-468-9325
dschemelia@tiberend.com
[1] https://www.nature.com/articles/6603581
[2] https://www.nature.com/articles/s41523-020-0153-3
SOURCE Coeptis Therapeutics
Continued work means that there's some possible good results... $COEP
"We are very excited to continue our work with the University of Pittsburgh to advance the development of SNAP-CAR towards a potential first indication: HER2-expressing ovarian cancer," said Dave Mehalick, President and CEO of Coeptis Therapeutics Holdings. "If successful, this could represent a potential breakthrough in the treatment of HER2-positive cancers and the applicability of CAR T to treat a range of solid tumors, including ovarian and breast cancer, as well as hematologic cancers. We look forward to working with Dr. Lohmueller, Dr. Deiters, and the research team at the University of Pittsburgh, as well as IQVIA, to prioritize the initial target indication for advancing SNAP-CAR through the IND process and into the clinic."
$COEP trading just over 25% of its 10-day average volume in just over an hour... holding steady in price.
$COEP Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program https://finance.yahoo.com/news/coeptis-therapeutics-enters-sponsored-research-123000182.html
Really like their latest news...
$COEP News January 31, 2023
Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program
https://finance.yahoo.com/news/coeptis-therapeutics-enters-sponsored-research-123000182.html
Looks like this is going on sale now…. Might be picking up more soon
Thinking $2 will be a big resistance. Once that’s broke, should open up.
Followers
|
109
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
11906
|
Created
|
03/04/10
|
Type
|
Free
|
Moderators |
"Coeptis Therapeutics is a biopharmaceutical
company developing innovative cell therapy
platforms for patients with cancer."
OUR MISSION:
"TO IMPROVE OUTCOMES FOR PATIENTS WITH CANCER"
Various immunotherapies for CD38+ tumors are designed to find and kill cells that express the CD38 antigen;
therefore, CD38+ NK cells are likely to become collateral damage and with their eradication, the overall anti-tumor response is suboptimal.
To protect CD38+ Natural Killer (NK) cells so that functional disease-targeting NK cells will not be eradicated, enabling their co-existence with
CD38 targeting therapies, and thus allowing tumor killing and immune surveillance.
Modified NK cells that are co-administered with select monoclonal antibodies and/or other CD38 targeting immunotherapies are in pre-clinical development to enhance and
maximize tumor kill via combinatorial approaches otherwise not possible.
Coeptis Therapeutics Holdings, Inc. conducts its commercial operations primarily through its wholly-owned subsidiary Coeptis Pharmaceuticals, Inc.
Coeptis Therapeutics Holdings, Inc.
Corporate Headquarters
105 Bradford Road, Suite 420
Wexford, PA 15090
+1 (724) 934-6467
As of March 30, 2023 • 12:02 PM ET
As of March 30, 2023 • 12:02 PM ET
DATE/TIME | SOURCE | NEWS RELEASE |
---|---|---|
03/27/2023 10:47 AM EDT | SeekingAlpha | NBRV, JNCE and ALIM among healthcare movers |
03/27/2023 08:52 AM EDT | SeekingAlpha | IOVA, MQ and ONCS are among pre market gainers |
03/22/2023 08:30 AM EDT | InvestorBrandNetwork | InvestorNewsBreaks - Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP) Tech Spotlighted in Article in Peer-Reviewed Translational Medicine Journal |
06/23/2022 05:27 PM EDT | SeekingAlpha | I-Mab Valuation Offers A Biotech Investment Opportunity |
04/22/2022 03:00 PM EDT | SeekingAlpha | Catalyst watch: Apple earnings, Twitter drama and media eyes on NAB Show |
04/19/2022 01:50 PM EDT | SeekingAlpha | Coeptis Therapeutics to merge with SPAC Bull Horn, uplist to Nasdaq |
04/13/2022 07:48 AM EDT | SeekingAlpha | Statera Biopharma stock soars 31% on potential drug platform acquisition by Coeptis Therapeutics |
05/18/2021 08:53 AM EDT | SeekingAlpha | Coeptis inks exclusive option agreements with VyGen-Bio |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for
information purposes only.
No stock exchange has approved or disapproved of the information here.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |